Less Ads, More Data, More Tools Register for FREE

Pin to quick picksApax Global Alpha Regulatory News (APAX)

  • This share is currently suspended. It was suspended at a price of 164.40
  • There is currently no data for APAX

Form 8.3 - APAX LN

8 Aug 2025 15:00

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:

Sand Grove Capital Management LLP

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

Fund(s) for which Sand Grove Capital Management LLP serves as the Investment Manager or Discretionary Sub-Advisor

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Apax Global Alpha Limited

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

07 August 2025

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state “N/A”

N/A

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

Ordinary NPV

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

10,885,047

2.26%

(2) Cash-settled derivatives:

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

TOTAL:

10,885,047

2.26%

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

Ordinary NPV

Purchase

744,334

1.88537 EUR

Ordinary NPV

Purchase

485,184

163.5p

Ordinary NPV

Purchase

270,483

163.5p

(b) Cash-settled derivative transactions

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii) Exercise

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?

No

Date of disclosure:

08 August 2025

Contact name:

James Evans

Telephone number:

+44 20 3161 0743

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel’s Market Surveillance Unit.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250808968083/en/

Copyright Business Wire 2025

Date   Source Headline
7th May 20247:00 amRNSApax IX agrees to sell Healthium
2nd May 20247:00 amRNSAudit Committee Change
2nd May 20247:00 amRNSResult of AGM
2nd May 20247:00 amRNSQuarterly Results to 31 March 2024
24th Apr 20247:00 amRNSApax Funds to acquire IANS
18th Apr 20247:00 amRNSApax Funds To Acquire Zellis Group
5th Apr 20249:58 amRNSDirector/PDMR Shareholding
4th Apr 20242:02 pmRNSDirector/PDMR Shareholding
27th Mar 20247:00 amRNSNotice of Capital Markets Day
22nd Mar 202410:08 amRNSHolding in Company
11th Mar 20245:17 pmRNSPurchase of Ordinary Shares under IMA
5th Mar 20247:00 amRNS2023 Annual Dividend Declaration
5th Mar 20247:00 amRNSNotice of AGM
5th Mar 20247:00 amRNS2023 Annual Report and Accounts
5th Mar 20247:00 amRNS2023 Final Results
1st Mar 20242:00 pmRNSRetirement of Chris Ambler from the Board
28th Feb 20247:00 amRNSApax Funds Acquire IES
8th Feb 20247:00 amRNSEstimated Adjusted NAV as at 31 December 2023
2nd Feb 20247:00 amRNSApax Funds Acquire WGSN
4th Dec 20233:00 pmEQSHardman & Co Q&A on Apax Global Alpha: Hidden gems strategy delivering new investment opportunities
23rd Nov 202312:43 pmEQSHardman & Co Research on Apax Global Alpha (APAX): “Hidden Gems” strategy: green shoots into live deals
17th Nov 202312:58 pmRNSDirector/PDMR Shareholding
15th Nov 20237:00 amRNSApax Funds Invest in Petvisor
9th Nov 20237:00 amRNSQuarterly Results to 30 September 2023
27th Oct 20237:00 amRNSApax Funds Acquire GAN Integrity
12th Oct 20232:15 pmEQSHardman & Co Q&A on Apax Global Alpha (APAX): Confirming strong underlying competitive advantages
11th Oct 20237:00 amRNSApax Funds acquire Bazooka Candy Brands
5th Oct 20237:00 amRNSNotice of Q3 2023 Financial Results
2nd Oct 20237:00 amRNSDirectorate Change
25th Sep 20235:06 pmRNSHolding in Company
25th Sep 20232:45 pmEQSHardman & Co Research on Apax Global Alpha (APAX): Resilience in face of rising interest rates
12th Sep 202311:30 amRNSDirector/PDMR Shareholding
6th Sep 20237:02 amRNS2023 Interim Dividend
6th Sep 20237:01 amRNS2023 Interim Report and Accounts
6th Sep 20237:00 amRNS2023 Interim Results Highlights
7th Aug 20237:00 amRNSEstimated Adjusted NAV as at 30 June 2023
1st Aug 20237:00 amRNSFunds advised by Apax to acquire Palex
20th Jul 20234:35 pmEQSHardman & Co Q&A on Apax Global Alpha (APAX) Capital Markets Day: value added by the manager
5th Jul 20233:50 pmEQSHardman & Co Research on Apax Global Alpha (APAX) 2023 Capital Markets Day: accessing hidden gems
2nd Jun 20237:00 amRNSFunds advised by Apax invest in Swing Education
23rd May 20237:00 amRNSNotice of Capital Markets Day
16th May 20237:00 amRNSFunds advised by Apax to acquire IBS Software
4th May 20237:00 amRNSResult of AGM
4th May 20237:00 amRNSQuarterly results for 31 March 2023
21st Mar 20232:05 pmEQSHardman & Co Q&A on Apax Global Alpha (APAX): 2022 results adding value to companies leads to outperformance
14th Mar 20232:05 pmEQSHardman & Co Research on Apax Global Alpha (APAX): Outperformance by adding value to companies
13th Mar 20237:00 amRNSUpdate relating to SVB
2nd Mar 20237:00 amRNS2022 Annual Dividend Declaration
2nd Mar 20237:00 amRNSNotice of AGM
2nd Mar 20237:00 amRNS2022 Annual Report and Accounts

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.